Entrada Therapeutics Analyst Ratings
Entrada Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/27/2023 | 72.56% | HC Wainwright & Co. | $25 → $20 | Maintains | Buy |
| 09/22/2023 | 115.7% | HC Wainwright & Co. | → $25 | Reiterates | Buy → Buy |
| 08/09/2023 | 115.7% | HC Wainwright & Co. | → $25 | Reiterates | Buy → Buy |
| 08/02/2023 | 115.7% | HC Wainwright & Co. | → $25 | Reiterates | Buy → Buy |
| 05/24/2023 | 115.7% | HC Wainwright & Co. | → $25 | Reiterates | Buy → Buy |
| 04/03/2023 | 115.7% | HC Wainwright & Co. | → $25 | Initiates Coverage On | → Buy |
| 11/08/2022 | 55.31% | Goldman Sachs | $13 → $18 | Maintains | Neutral |
| 08/16/2022 | 12.17% | Goldman Sachs | $10 → $13 | Maintains | Neutral |
| 05/24/2022 | -13.72% | Goldman Sachs | $22 → $10 | Maintains | Neutral |
| 11/24/2021 | — | Evercore ISI Group | Initiates Coverage On | → Outperform | |
| 11/23/2021 | — | Cowen & Co. | Initiates Coverage On | → Outperform | |
| 11/23/2021 | 150.22% | Goldman Sachs | → $29 | Initiates Coverage On | → Neutral |
| 日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
|---|---|---|---|---|---|
| 11/27/2023 | 72.56% | HC Wainwright & Co. | 25 美元 → 20 美元 | 维护 | 买 |
| 09/22/2023 | 115.7% | HC Wainwright & Co. | → 25 美元 | 重申 | 购买 → 购买 |
| 08/09/2023 | 115.7% | HC Wainwright & Co. | → 25 美元 | 重申 | 购买 → 购买 |
| 08/02/2023 | 115.7% | HC Wainwright & Co. | → 25 美元 | 重申 | 购买 → 购买 |
| 05/24/2023 | 115.7% | HC Wainwright & Co. | → 25 美元 | 重申 | 购买 → 购买 |
| 04/03/2023 | 115.7% | HC Wainwright & Co. | → 25 美元 | 启动覆盖范围开启 | → 购买 |
| 2022 年 8 月 11 日 | 55.31% | 高盛 | 13 美元 → 18 美元 | 维护 | 中立 |
| 08/16/2022 | 12.17% | 高盛 | 10 美元 → 13 美元 | 维护 | 中立 |
| 2022 年 5 月 24 日 | -13.72% | 高盛 | 22 美元 → 10 美元 | 维护 | 中立 |
| 11/24/2021 | — | Evercore ISI 集团 | 启动覆盖范围开启 | → 跑赢大盘 | |
| 11/23/2021 | — | Cowen & Co. | 启动覆盖范围开启 | → 跑赢大盘 | |
| 11/23/2021 | 150.22% | 高盛 | → 29 美元 | 启动覆盖范围开启 | → 中立 |
What is the target price for Entrada Therapeutics (TRDA)?
Entrada Therapeutics（TRDA）的目标价格是多少？
The latest price target for Entrada Therapeutics (NASDAQ: TRDA) was reported by HC Wainwright & Co. on November 27, 2023. The analyst firm set a price target for $20.00 expecting TRDA to rise to within 12 months (a possible 72.56% upside). 6 analyst firms have reported ratings in the last year.
HC Wainwright & Co. 于2023年11月27日公布了Entrada Therapeutics（纳斯达克股票代码：TRDA）的最新目标股价。该分析公司将目标股价定为20.00美元，预计TRDA将在12个月内升至12个月内（可能上涨72.56％）。去年有6家分析公司公布了评级。
What is the most recent analyst rating for Entrada Therapeutics (TRDA)?
分析师对Entrada Therapeutics（TRDA）的最新评级是多少？
The latest analyst rating for Entrada Therapeutics (NASDAQ: TRDA) was provided by HC Wainwright & Co., and Entrada Therapeutics maintained their buy rating.
HC Wainwright & Co. 提供了Entrada Therapeutics（纳斯达克股票代码：TRDA）的最新分析师评级，Entrada Therapeutics维持买入评级。
When is the next analyst rating going to be posted or updated for Entrada Therapeutics (TRDA)?
Entrada Therapeutics（TRDA）的下一次分析师评级何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Entrada Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Entrada Therapeutics was filed on November 27, 2023 so you should expect the next rating to be made available sometime around November 27, 2024.
分析师在进行了广泛的研究后得出了股票评级，其中包括浏览公开财务报表，与Entrada Therapeutics的高管和客户交谈，以及听取财报电话会议。大多数分析师每三个月做一次这样的评级，因此每家公司每年应该获得4次评级。Entrada Therapeutics的最新评级是在2023年11月27日公布的，因此您应该预计下一个评级将在2024年11月27日左右公布。
Is the Analyst Rating Entrada Therapeutics (TRDA) correct?
分析师对Entrada Therapeutics（TRDA）的评级是否正确？
While ratings are subjective and will change, the latest Entrada Therapeutics (TRDA) rating was a maintained with a price target of $25.00 to $20.00. The current price Entrada Therapeutics (TRDA) is trading at is $11.59, which is out of the analyst's predicted range.
尽管评级是主观的，并且会发生变化，但最新的Entrada Therapeutics（TRDA）评级维持不变，目标股价为25美元至20.00美元。Entrada Therapeutics（TRDA）目前的交易价格为11.59美元，超出了分析师的预期区间。